CASE REPORT

Anti-NMDA receptor encephalitis and MOG-associated demyelination – a case report with long-term follow-up and a systematic review

Klaus Berek1, Astrid Grams2, Christian Uprimny3, Manuela Prieschl1, Melanie Ramberger1, Iris Unterberger1, Florian Deisenhammer1, Markus Reindl1 and Harald Hegen1*

Abstract

Background: Overlap syndromes of anti-NMDA receptor encephalitis and MOG-mediated demyelination have been reported. In this case we provide a long-term longitudinal follow-up of clinical and imaging characteristics as well as of antibody dynamics.

Case presentation: We report a 32-year-old male patient who presented with psychosis, decreased consciousness and movement disorders and was tested positive for anti-NMDA receptor antibodies. Forty-four months after symptom onset and diagnosis of autoimmune encephalitis, he suffered from relapse. At this time, the patient developed anti-MOG and anti-Caspr2 antibodies. Treatment with plasmapheresis, steroids and rituximab eventually led to substantial clinical and radiological improvement. Anti-Caspr2 antibodies persisted, anti-NMDA receptor antibodies decreased, while anti-MOG antibodies turned negative again.

Conclusion: We provide long-term longitudinal follow-up of a patient with anti-NMDA receptor encephalitis who developed triple antibody positivity at the time of relapse. Antibody dynamics were associated with clinical disease course.

Keywords: Anti-N-Methyl-D-Aspartate, NMDA, Encephalitis, Demyelination, Myelin Oligodendrocyte Glycoprotein, Case report

Background

Anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis and Myelin Oligodendrocyte Glycoprotein (MOG) associated disorders are both immune-mediated inflammatory disorders of the central nervous system [1, 2]. Patients with NMDAR encephalitis usually present with a clinical syndrome including psychosis, behavioural changes, amnesia and epileptic seizures, frequently followed by dyskinesia and decreased levels of consciousness [2], while patients with MOG associated disorders typically present with a demyelinating syndrome reaching from ADEM-like phenotype to isolated syndromes, such as myelitis or optic neuritis [1]. Overlap syndromes of these two disease entities have been reported, i.e. either MOG immunoglobulin G (IgG) and demyelinating aspects have been found in patients with anti-NMDAR encephalitis [3–21], or vice versa NMDAR IgG in patients with demyelinating CNS disease [22].

*Correspondence: harald.hegen@i-med.ac.at
1 Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
However, none of these reports provided long-term data of the clinical disease course, of antibody titres and radiological findings. Here, we report the case of male patient with anti-NMDAR encephalitis who developed MOG and Caspr2 IgG during the disease course.

Case presentation
A 32-year old man with a pre-morbid modified Rankin Scale (mRS) score of 0 was referred to primary medical center due to psychosis, behavioral disorders and consecutively movement disorder, decrease in consciousness and hypoventilation. Emergency cerebral magnetic resonance imaging (MRI) revealed a normal scan. Cerebrospinal fluid (CSF) analysis showed mild pleocytosis with lymphocytes (white blood cell [WBC] count 38/µl) and CSF-restricted oligoclonal bands (OCB; Pattern II) [23]. Additionally, Computed Tomography (CT) scan and consecutive bacteriological examination of tracheal aspirate identified an atypical pneumonia due to pseudomonas aeruginosa.

The patient was referred to the Medical University of Innsbruck, where a thorough diagnostic work-up was done. Electroencephalography (EEG) showed continuous bilateral slowing without epileptic discharges. Laboratory examination by a commercially available cell based assay (Euroimmun, Lübeck, Germany) revealed positive NMDAR IgG in serum and CSF (serum titer 1:2560). Presence of IgG directed to MOG (serum titer 1:40; considered negative) and aquaporin-4 (AQP-4) were excluded by an in-house test as previously described [24, 25]. Ri, Yo, Hu, Ma2, Amphiphysin, CV2 IgG were negative (determined by a commercially available cell based assay [Euroimmun]) were found in serum and CSF (titer of 1:100), but not in CSF. Treatment with IVMP (1000 mg three days, 500 mg two days and oral tapering) initially led to a slight clinically improvement and afterwards a short stable period, however, was followed by further worsening of psychiatric symptoms after two months. Therefore, treatment with rituximab (375 mg/m² body surface) was initiated at month 46, which was then followed by clinical improvement of neuropsychiatric symptoms. MRI findings and antibody titers displayed also slow regression (Fig. 1E-J).

Until the last follow-up at month 66 the patient had received five cycles of rituximab and showed a substantial clinical and radiological improvement (Figs. 1 and J; 2). mRS score was 1. NMDAR-IgG (at month 66) and Caspr2-IgG (at month 58) remained detectable by means of immunofluorescence until last follow-up in serum specimens, while serum MOG-IgG (at month 66) were below the cut-off titer (titer 1:80). Clinical, diagnostic and therapeutic key points are detailed in Fig. 2.

Review of the literature
Data of clinical and radiological presentations of MOG-positive anti-NMDAR-encephalitis are still scarce and were published in form of case series and reports. We performed a systematic literature search to provide an overview on demographic, clinical, serological and radiological findings in double positive anti-NMDAR and anti-MOG patients. Therefore, we searched the medical database PUBMED on January 01, 2022 using the term “MOG” AND “NMDAR” AND “overlap” and additionally checked respective reference lists. We considered articles published since January 2000 and written in English (Supplemental Figure). A summary of our results is displayed in Table 1 and the Supplemental Table C: Follow-Up after NMDAR-encephalitis.

We included 31 cases from literature. The age of the predominantly male patients (male: 74.2%) ranged between 3 and 54 years, with a peak within young
adulthood (median age at onset: 25). Every patient suffered in median one demyelinating event during or after NMDAR-encephalitis. Similarly, also MOG IgG were most often detected concurrently with NMDAR-encephalitis. The median time between onset of encephalitis and MOG-positivity was 0 months, ranging from -240 (indicating positive MOG IgG before onset of encephalitis) to 35 months. The detection of MOG IgG is usually linked to a clinical demyelinating event (74%). NMDAR IgG are more frequently detected within CSF, while MOG IgG are more often found in serum samples. Eleven (44%) of 25 patients tested for OCB show positive results (Pattern II or III [27]). The WBC ranged from 0 to 576, with a median of 43/µl.

Reported radiological findings of MOG IgG positive NMDAR-encephalitis patients are displayed in the Supplemental Table. Of 31 reported cases, 70 MRI scans were available. 18 were conducted during NMDAR-encephalitis, based on positive NMDAR-IgG titers and typical clinical alterations, at a time when clinical or serological (i.e. presence of MOG IgG) signs for demyelination were not present. 16 (89%) of these showed T2/ fluid-attenuated inversion recovery (FLAIR) hyperintense lesions, two (11%) Gd-enhancement and two normal results. In three cases (17%) bilateral, in 14 (78%) supratentorial and in two (11%) infratentorial lesions were detected. Lesions within the spinal cord were not described.

52 MRI scans were carried out during a demyelinating event, indicated by typical clinical symptoms and/or serological detection of anti-MOG IgG. 45 (86%) of these showed T2/FLAIR-hyperintensities, 16 (30%) Gd-enhancement and five (10%) a normal result. According the regions where lesions were found, 36 (69%) MRI scans showed supratentorial, 32 (62%) infratentorial and four (8%) spinal lesions. Bilateral lesions were described in 25 (48%) scans. So far, only one case study included an 18F-FDG PET/CT work-up, which showed a normal result [7]. Another study, added information about single photon emission computed tomography (SPECT), which revealed decreased technetium uptake within regions of the frontal lobe, brainstem and basal ganglia [4]. No results of FET PET/CT scans have been reported so far.

Discussion
Overlap syndromes with the occurrence of MOG-IgG in patients with NMDAR encephalitis are a known but rare phenomenon and have been reported only in few patients [3–13, 15–21]. The present case provides a long-term follow-up over more than 5 years with detailed, longitudinally collected, clinical and radiological findings as well as antibody dynamics. Furthermore, we report triple antibody positivity with detection of Caspr2 IgG in serum at the time of relapse.
In our patient, we observed that NMDAR IgG titers declined after starting effective immunotherapy (PLEX, IVMP) concurrently with clinical amelioration, increased at the time of relapse and decreased again with treatment escalation (rituximab) and further clinical improvement. During relapse, i.e. the second episode of clinical worsening, demyelinating lesions on MRI were detected together with MOG IgG. After immune treatment of this overlap syndrome, also MOG titers and MRI findings decreased concurrently with clinical improvement.

The association of both NMDAR IgG titer with the clinical course of NMDAR encephalitis [2] and of MOG IgG titer with the clinical course of MOGAD have been reported earlier [1]. However, it still remains unclear whether IgG kinetics may mainly be caused by an intense treatment regimen (e.g. PLEX), or may in fact reflect the...
Table 1  Demographic, clinical and serological findings in MOG IgG positive patients with NMDAR encephalitis

| Ref | Demographics | Clinics | Serum | CSF |
|-----|--------------|---------|-------|-----|
|     | Patient Number | Age | Sex | Graus criteria fulfilled | Demyelinating episodes, n° | Follow-up, Mo | Time E – MOG+, Mo | DE symptoms | MOG-IgG status | NMDAR-IgG status | MOG-IgG status | NMDAR-IgG status | OCB status | WBC/µl |
| [3] | 1 | 48 | F | Yes | 2 | 60 | 18 | Yes | positive | positive | positive | positive | positive | positive | 150 |
| [3] | 2 | 17 | M | Yes | 2 | 9 | 3 | Yes | n.a | Not applicable | positive | positive | positive | negative | 3 |
| [3] | 3 | 27 | F | Yes | 5 | 108 | -48 | Yes | positive | negative | positive | positive | positive | 66 |
| [3] | 4 | 34 | M | Yes | 2 | 22 | 3 | Yes | positive | negative | positive | positive | negative | 164 |
| [3] | 5 | 10 | M | Yes | 1 | 144 | -96 | Yes | positive | negative | positive | positive | negative | 9 |
| [3] | 6 | 29 | M | Yes | 1 | 41 | 36 | Yes | positive | n.a | positive | positive | negative | 0 |
| [3] | 7 | 38 | M | Yes | 2 | 60 | -22 | Yes | positive | negative | positive | positive | negative | 2 |
| [3] | 8 | 4 | F | Yes | 1 | 7 | 0 | Yes | positive | n.a | positive | positive | n.a | 43 |
| [3] | 9 | 6 | M | Yes | 1 | 2,5 | 0 | Yes | positive | negative | positive | positive | positive | 44 |
| [15] | 10 | 9 | F | Yes | 1 | 18 | 0,5 | Yes | positive | positive | positive | positive | negative | 3 |
| [11] | 11 | 31 | M | No | 2 | 15 | 0 | Yes | positive | negative | n.a | positive | negative | 8 |
| [12] | 12 | 54 | M | Yes | 0 | 3 | 0 | Yes | positive | n.a | n.a | positive | negative | 28 |
| [8] | 13 | 3 | F | Yes | 3 | 252 | -240 | Yes | positive | negative | positive | positive | negative | 0 |
| [8] | 14 | 23 | M | Yes | 3 | 44 | -44 | Yes | positive | negative | negative | positive | positive | 0 |
| [8] | 15 | 6 | M | Yes | 5 | 54 | 0 | Yes | positive | positive | positive | negative | positive | 8 |
| [8] | 16 | 25 | M | Yes | 1 | 0 | 0 | Yes | positive | positive | positive | positive | positive | 96 |
| [8] | 17 | 9 | M | Yes | 2 | 18 | 18 | Yes | positive | positive | negative | positive | negative | 2 |
| [11] | 18 | 47 | M | na | 2 | 60 | 0 | No | positive | positive | positive | positive | negative | 16 |
| [4] | 19 | 36 | F | Yes | 1 | 44,5 | 0 | No | positive | n.a | n.a | positive | positive | 116 |
| [20] | 20 | 10 | F | Yes | 0 | 36 | 12 | No | positive | n.a | n.a | positive | negative | 576 |
| [19] | 21 | 6 | M | Yes | 0 | 3 | 0 | Yes | positive | n.a | n.a | positive | positive | 0 |
| [18] | 22 | 29 | M | Yes | 1 | 4 | 2 | Yes | positive | n.a | n.a | positive | positive | 39 |
| [16] | 23 | 12 | M | Yes | 0 | 1,5 | 0 | No | positive | positive | na | positive | na | 91 |
| [21] | 24 | 14 | F | Yes | 3 | 44 | -4 | No | positive | positive | n.a | positive | negative | 256 |
| [21] | 25 | 10 | M | Yes | 0 | 6 | 0 | Yes | positive | positive | n.a | positive | na | 96 |
| [17] | 26 | 19 | M | Yes | 2 | 37 | 18 | Yes | positive | negative | negative | positive | n.a | 292 |
| [6] | 27 | 27 | M | Yes | 0 | 4 | 0 | Yes | n.a | n.a | positive | positive | n.a | 5 |
| [10] | 28 | 38 | M | Yes | 1 | 6 | 0 | Yes | positive | positive | n.a | positive | n.a | 88 |
| [5] | 29 | 37 | M | Yes | 0 | 2 | 0 | No | positive | positive | positive | positive | negative | 50 |
| [9] | 30 | 39 | M | Yes | 2 | 60 | 0 | No | positive | n.a | positive | positive | n.a | 112 |
### Table 1 (continued)

| Ref | Demographics | Clinics | Serum | CSF |
|-----|--------------|---------|-------|-----|
|     | Patient Number | Age | Sex | Graus criteria fulfilled<sup>a</sup> | Demyelinating episodes, n<sup>b</sup> | Follow-up, Mo<sup>c</sup> | Time E – MOG +, Mo | DE symptoms | MOG-IgG status | NMDAR-IgG status | MOG-IgG status | NMDAR-IgG status | OCB status | WBC/µl |
| [7] | 31 | 30 | M | Yes | 0 | 12 | 0 | Yes | positive | positive | positive | n.a | n.a | n.a |
| Total | 31 | 25 (3–54) | Female: 8 (25.8%) | 29 (94%) | 1 (0–5) | 18 (0–252) | 0 (-240–36) | 23 (74%) | Positive: 29 | Positive: 10 | Positive: 16 | Positive: 30 | Positive: 11 | 43 (0–576) |

Legend: CSF Cerebrospinal fluid, DE Demyelination, E NMDAR-encephalitis, F Female, IgG Immunoglobulin G, MO Months, M Male, MOG Myelin oligodendrocyte glycoprotein, MOG+ MOG IgG positivity, N Number, NMDAR N-methyl-D-aspartate receptor, OCB Oligoclonal bands, Ref Reference, WBC White blood cell count

<sup>a</sup> Diagnostic criteria for definite NMDAR encephalitis according to Graus et al. [26]

<sup>b</sup> Demyelinating episodes during or after NMDAR-encephalitis were considered

<sup>c</sup> Follow-Up after NMDAR-encephalitis
clinical course. It has been demonstrated that PLEX may lead to a marked reduction (of up to 97%) of autoantibodies in autoimmune encephalitis (AE), however, approximately one third of patients does not experience a clinical improvement [28].

The literature review of double positive (NMDAR IgG and MOG IgG) patients revealed that in the majority of reported cases MOG IgG were detected for the first time simultaneously with the first NMDAR IgG detection (Table 1). In our patient, we detected MOG IgG only at the time of NMDAR encephalitis relapse, i.e. 44 months after the first event (Fig. 2). This might be explained by the heterogeneity of the so far reported cases of double positive patients. Reported cases subsume patients with MOG positivity before, simultaneous or after NMDAR encephalitis. However, this may also implicate a pathophysiological difference. Pathophysiology might probably be different in patients with a known MOG positive demyelinating disease and a later occurring NMDAR encephalitis [3, 8, 21] compared to patients with NMDAR encephalitis who later suffer a demyelinating relapse triggered by MOG IgG [3, 8, 15, 17, 18, 20]. Furthermore, some reported cases of simultaneous IgG positivity had a medical history of previous optic neuritis and were tested for MOG IgG for the first time at the onset of NMDAR encephalitis [11, 17, 20]. Overall, we did not find any obvious differences in our literature review of clinical, laboratory, or radiographic features between patients developing MOG IgG before or after NMDAR encephalitis.

At this point a possible limitation can be identified within the borderline positive MOG IgG titers. Indeed, titers of 1:320 have already been reported within Multiple Sclerosis and other neurological disorders. Therefore, an unspecific finding cannot be ruled out with certainty [24, 29]. From a clinical perspective, it has to be pointed out, that at relapse our patient actually presented with symptoms more consistent with encephalitis relapse rather than with a demyelinating disorder. Indeed, around 74% (23/31) of the patients in our literature review showed classical demyelinating symptoms (e.g., hemihypesthesia, diplopia, hemiparesis, vertigo) alongside with MOG IgG positivity. Most of them, 87% (20/23), revealed simultaneously T2 or FLAIR hyperintense lesions on cerebral MRI scans (two showed optic nerve enhancement). Nevertheless, the remaining 26% (8/31) of patients showed also asymptomatic lesion. Altogether, one might avoid routine MOG IgG testing in patients with NMDAR encephalitis due to the increase of false positive results, however, in patients with either a clinical or imaging findings of demyelination, MOG IgG testing might be reasonable. As patients with NMDAR encephalitis plus CNS demyelination show worse outcome, evidence of further autoimmunity might also have an impact on treatment decision.

It may be of special interest that since the time of the demyelinating relapse and occurrence of MOG IgG, our patient was tested positive for Caspr2-IgG in serum. So far, one prior case study of one patient reported a triple positivity of anti-NMDAR, anti-MOG and anti-Caspr2-IgG, and similar to our case Caspr2-IgG remained positive until the end of follow-up [7]. A further similarity subsumes the clinical presentation, as “behavioral changes” and “episodic memory loss” were also described in the previous case report [7]. However, symptoms occurring in both, Caspr2 and NMDAR encephalitis are difficult to attribute to a distinct entity [30, 31]. MRI findings of the previously published case and of our case are contrasting, as we did not observe bilateral, cingulate and hippocampal lesions [7]. Furthermore, in our case Caspr2 IgG were detectable only in serum, whereas the other study found Caspr2 IgG also in CSF. It is known, that Caspr2 IgG may be detected in just one compartment, i.e. either in blood or CSF, and that the amount of Caspr2 IgG is usually lower in CSF than in serum [30, 32]. In general, the coincidence of IgG associated with AE (i.e. NMDAR IgG, Caspr2 IgG, etc.) has infrequently been reported before. Besides the above case report [7], a recent study screened 42,032 patients for AE IgG. In 28 patients, multiple ($\geq 2$) AE IgG, in two patients three and in one patient four distinct AE IgG were detected. The most common combination was Caspr2 and leucine-rich, glioma inactivated 1 (LG11) IgG, which was revealed in 8 patients [33]. Therefore, such a double, triple or even quadruple positivity is a rare immunological phenomenon. It has been hypothesised that this phenomenon may partly be caused by a common immunologic trigger [33], which is a possibility for the above mentioned coexistence of Caspr2 and LG11 IgG both targeting parts of the voltage-gated potassium channel complex [34]. However, in our case of a triple positivity such a common immunologic trigger is unlikely. Therefore, taking up an earlier hypothesis, it may rather be explained by a general susceptibility for autoimmune processes [35].

Nevertheless, the possibility of false positive Caspr2-IgG results has to be considered. Indeed, it has recently been reported, that the drawback of a high sensitivity of commercially CBA for the detection of Caspr2 is a higher risk for false positive results [36]. Nonetheless, we observed repeatedly positive Caspr2 IgG from relapse onset, until end of our follow-up, which excludes the possibility of false positive result, even if unspecific cross-reactivity cannot be excluded.

Within NMDAR encephalitis, typical MRI changes include white matter changes within diffusion tensor imaging (DTI), which are most often found in the cingulum and correlate with disease course [37]. However, normal MRI results even with severe clinical symptoms are a well-known phenomenon in a majority of NMDAR
encephalitis patients [31, 37–39]. Patients suffering from MOG-antibody disease show normal or un­specific results in brain MRI scans in approximately two of three cases [40], although T2 hyperintensities predominantly located in infratentorial regions and brainstem can be found [41].

Regarding radiological findings in double positive patients we provide a review of the literature within Supplemental Table, from where it may be deduced that MRI scans at the time of demyelination show more frequently Gd-enhancing, bilateral, infratentorial and spinal cord lesions. In our patient, all MRI scans during the first, non-demyelinating episode revealed normal results, while MRI scans during the demyelinating relapse yielded T2 hyper-, T1 hypointense, Gd-enhancing lesions in the gray matter of the left Gyrus frontalis. Similar findings (i.e. normal MRI during NMDAR encephalitis and T2 hyperintense lesions during a second demyelinat­ing event) have been reported in 11% of the cases. The radiological follow-up of our patient revealed remission of Gd-enhancement one month after treatment initiation and regression of T2-hyperintense lesions subsequently. In the last MRI scan at month 66, only subtle sequelae in form of a post-inflammatory gliosis in the left frontal lobe was found. Taking into account serological findings of our patient an association of MOG-IgG with MRI findings may be hypothesized, as negative MOG-IgG titers were found simultaneously with normal MRI findings and decreasing MOG-IgG titers were found simultaneously with receding MRI findings.

A further novelty of our case is detailed information about 18F-FDG PET and FET PET within double positive anti-NMDAR and anti-MOG patients. Published studies are subsumed in the Supplemental Table. Previous studies have already reported that in NMDAR encepha­litis 18F-FDG PET can reveal both hypo- and hyperme­tabolism [42]. With our case, we contribute longitudinal data of four 18F-FDG PET scans and an FET PET scan. During the first, non-demyelinating episode no pathological finding was detectable in the brain. At the time of the demyelinating relapse, FET PET detected hyper­metabolism in the areas of T2 hyperintensity of the cor­responding MRI scans, whereas 18F-FDG PET showed a diminished metabolism within these areas.

**Conclusion**

We provide detailed longitudinal data of a patient with NMDAR encephalitis. At a second event, he presented with demyelinating brain lesions and MOG IgG as well as Caspr2-IgG. NMDAR and MOG IgG titers diminished alongside with clinical and radiological ame­lioration after IVMP, PLEX and rituximab treatment. Furthermore, we provide a systematic review regarding MOG IgG positive NMDAR encephalitis.

**Abbreviations**

18F-FDG: 18F-fluoro-2-deoxy-D-glucose; AE: Autoimmune encephalitis; AQP-4: Aquaporin-4; Caspr2: Contactin-associated protein-like 2; CBA: Cell-based assay; CSF: Cerebrospinal fluid; CT: Computed Tomography; DTT: Diffusion tensor imaging; EEG: Electroencephalography; FET: O-(2[18F]fluoroethyl)-L-tyrosine; FLAIR: Fluid-attenuated inversion recovery; IVMP: Intravenous methylprednisolone; MOG: Myelin Oligodendrocyte Glycoprotein; MRI: Magnetic resonance imaging; mRS: Modified Rankin Scale; NMDAR: N-methyl-D-aspartate-receptor; OCB: Oligoclonal bands; OPS: Organic psycho syndrome; PET: Positron emission tomography; PLEX: Plasmapheresis; WBC: White blood cell.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12883-022-02974-x.

**Additional file 1: Supplemental Figure.** Flowchart of included articles.

**Additional file 2: Supplemental Table.** Radiological findings in MOG IgG positive patients with NMDAR encephalitis.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

KB has participated in acquisition and interpretation of the data and drafting the manuscript. AG has participated in acquisition of the data and reviewing the manuscript for intellectual content. CU has participated in acquisition of the data and reviewing the manuscript for intellectual content. MP has participated in acquisition and interpretation of the data and reviewing the manuscript for intellectual content. MR has participated in acquisition of the data and reviewing the manuscript for intellectual content. IU has participated in acquisition of the data and reviewing the manuscript for intellectual content. HH has participated acquisition and interpretation of the data and in drafting the manuscript. All authors have read and approved the manuscript.

**Funding**

There was no funding of this article.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

According to national regulations no ethical vote was needed because this is an anonymous case description. The patient signed a consent for publication. We adhered to the declaration of Helsinki and the Austrian Data Safety Authority instructions by anonymising all personal data.

**Consent for publication**

The patient signed a consent for publication. A copy of the written consent is available for review by the Editor of this journal.

**Competing interests**

Klaus Berek has participated in meetings sponsored by, received travel fund­ing from or received honoraria for acting as an advisor/speaker for Roche, Biogen, TEVA and Sanofi. Astrid Grams reports no conflicts of interest. Christian Uprimny reports no conflicts of interest. Manuela Prieschl reports no conflicts of interest. Melanie Ramberger reports no conflicts of interest. Iris Unterberger reports no conflicts of interest. Florian Diesenhammer has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Almirall, Alexion, Biogen, Cel- gene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and TEVA ratiopharm.
His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders) and review editor of Frontiers Neurology.

Markus Reindl is supported by research grants from the Austrian Science Fund (FWF project P32699), the Austrian Research Promotion Agency, Euroimmun and Roche; consulting fees and advisory board from Roche (to institution). He works at the Clinical Department of Medical University of Innsbruck which offers diagnostic testing for MOG and other autoantibodies.

Harald Hegen has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Merck, Novartis, Sanofi-Genezyme, Siemens, Teva, and received honoraria for acting as consultant for Biogen, Celgene, Novartis and Teva.

Author details
1 Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. 2 Department of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria. 3 Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Received: 3 June 2022   Accepted: 8 November 2022

Published online: 16 November 2022

References
1. Hegen H, Reindl M. Recent developments in MOG-IgG associated neurological disorders. Ther Adv Neurol Disord. 2020;13:1756286420945135.
2. Dalmau J, Armangue T, Planaguma J, Radosvevic M, Mannaara F, Lelystd F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045–57.
3. Titulaer MJ, Hofbberger R, Iizuka T, McCracken L, Cellucci T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3):411–28.
4. Aoe S, Kokudo Y, Takata T, Yamamoto M, Touge T, et al. Repeated anti-N-methyl-D-aspartate receptor encephalitis coexisting with anti-myelin oligodendrocyte glycoprotein antibody-associated diseases: a case report. Mult Scler Relat Disord. 2019;35:182–4.
5. Cao L, Ren L, Huang X. Clinical analysis of a patient simultaneously positive for antibodies of myelin oligodendrocyte glycoprotein and anti-N-methyl-D-aspartate receptor: a case report. Medicine (Baltimore). 2021;100(2):e24234.
6. Caparo-Zamalloa C, Alvarez-Toledo K, Yamanaque-Chunga C, Castro-Suarez S, Guevara-Silva E, Osorio-Marcantico V, et al. Autoimmune urology: co-occurrence of anti-NMDAR encephalitis and anti-MOG-associated disease, report of a case. J Neuroimmunol. 2021;358B.75663.
7. Chrenian A, Divya KP, Shetty SC, Kannoth S, Thomas B. Coexistence of MOG, NMDAR, CASPR2 antibody positivity: triumph over the triumvirate. Mult Scler Relat Disord. 2020;46:102468.
8. Fan S, Xu Y, Ren H, Guan H, Feng F, Gao X, et al. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Mult Scler Relat Disord. 2018;20:144–52.
9. Fujimori J, Takahashi T, Kaneko K, Atobe Y, Nakashima I. Anti-MOG encephalitis may develop concurrently with anti-MOG antibody-associated bilateral medial frontal cerebral cortical encephalitis and relapse with elevated CSF IL-6 and CXCL13. Mult Scler Relat Disord. 2021;47:102611.
10. Ren BY, Guo Y, Han J, Wang Q, Li ZW. Case report: anti-NMDA encephalitis with anti-MOG CNS demyelination after recurrent CNS demyelination. Front Neurol. 2021;12:639265.
11. Rojc B, Podnar B, Graus F. A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDA encephalitis: Different biological evolution of the two associated antibodies. J Neuroimmunol. 2019;328:86–8.
12. Zhou J, Tan W, Tan SE, Hu J, Chen Z, Wang K. An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDA encephalitis. J Neuroimmunol. 2019;320:107–10.
13. Zhou L, Zhang J, Li H, Li X, Huang Y, Wang M, et al. Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies. Mult Scler Relat Disord. 2017;18:90–2.
14. Martinez-Hernandez E, Guasp M, Garcia-Serra A, Maudes E, Arino H, Sepulveda M, et al. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology. 2020;94(22):e2302–10.
15. Yokoya K, Horii M, Yoshida A. Anti-myelin oligodendrocyte glycoprotein (MOG) antibody neuritis optica following anti-NMDA receptor encephalitis. Pediatr Int. 2016;58(9):953–4.
16. Ma J, Jiang L. VITAL encephalitis followed by anti-NMDAR encephalitis with concomitant MOG antibody-positive central nervous system demyelination in a child. Neurol Sci. 2020;41B:2303–5.
17. Nan D, Zhang Y, Han J, Jin T. Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis: a case report and review of the literature. Neurol Sci. 2021;42(3):847–55.
18. Perez CA, Aygu P, Gogia B, Harrison R, Samudralwar R. Overlapping autoimmune syndrome: a case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. J Neuroimmunol. 2020;339P.77124.
19. Sarigecili E, Cobanogullari MD, Komur M, Ouyar C. A rare concurrence: antibodies against myelin oligodendrocyte glycoprotein and N-methyl-D-aspartate receptor in a child. Mult Scler Relat Disord. 2019;28:101–3.
20. Taraschenko G, Zabard R. Overlapping demyelinating syndrome and anti-N-methyl-D-aspartate receptor encephalitis with seizures. Epilepsy Behav. Rep. 2019;12:100338.
21. Wegener-Panzer A, Cleavebard L, Wendel EM, Baumann M, Bertolini A, Hausler M, et al. Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e731.
22. Ramberger M, Brste G, Schanda K, Hofberger R, Rostasy K, Baumann M, et al. NMDA receptor antibodies: a rare association in inflammatory demyelinating diseases. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e141.
23. Freedman MS, Thompson J, Dessenhammer F, Giovannoni G, Grimesley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2006;62(6):865–70.
24. Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. 2020;7(2):e674.
25. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfalfer K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.
26. Graus F, Titulaer MJ, Balu R, Benseler S, Bengt CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
27. Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer R, et al. Guidelines on routine cerebrospinal fluid analysis: Report from an EFNS task force. Eur J Neurol. 2006;13(9):913–22.
28. Dogan Onugoren M, Golombek KS, Bengt CG, Abu-Tair M, Brand M, Bulla-Hellwig M, et al. Immunoadsorption therapy in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016;3(2):e207.
29. Sechi E, Bucic M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, et al. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol. 2021;78(6):741–6.
30. Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F, et al. Characterization of a subtype of autoimmune encephalitis with Anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 2016;73(9):1115–24.
31. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld M, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74.
32. Beng CG, Mirzadjanova Z, Baumgartner C, Onugoren MD, Grunwald T, Holtkamp M, et al. Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome. Eur J Neurol. 2017;24(1):175–86.
33. Kunchok A, McKeon A, Zekeridou A, Flanagan EP, Dubey D, Lennon VA, et al. Autoimmune/paraneoplastic encephalitis antibody biomarkers: frequency, age, and sex associations. Mayo Clin Proc. 2022;97(3):547–59.
34. van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017;13(5):290–301.

35. Kamm C, Zettl UK. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev. 2012;11(3):196–202.

36. Budhram A, Minian A, McFadden S, Edmond P, Bhayana V, Yang L. Neural Antibody Testing for Autoimmune Encephalitis: A Canadian Single-Centre Experience. Can J Neurol Sci. 2021;48(6):859-63. https://doi.org/10.1017/cjn.2021.23. Epub 2021 Feb 9. PMID: 33557967.

37. Finke C, Kopp UA, Scheel M, Pech LM, Soemmer C, Schlichting J, et al. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2013;74(2):284–96.

38. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36.

39. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(Pt 6):1655–67.

40. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474–81.

41. Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22(4):470–82.

42. Bordonne M, Chawki MB, Doyen M, Kas A, Guedj E, Tyvaert L, et al. Brain (18)F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41(12):3847–58.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions